Bilateral STN-DBS for Young-Onset Parkinson's Disease in a 41-Year-Old IT Professional with Severe Motor Fluctuations and Wearing-Off Dyskinesia

Condition

The patient was diagnosed with Parkinson’s disease at age 34 after presenting with a subtle right-hand tremor and slowed typing speed, and was referred to Dr. Guruprasad Hosurkar, a Neurologist in Bangalore for ongoing management. Levodopa-carbidopa initially controlled his symptoms well, the so-called honeymoon period, and he continued working full-time through several years of gradual dose increases.

Around eighteen months before this evaluation, the pattern changed. Each levodopa dose began wearing off well before the next was due, leaving him rigid and slow for stretches of one to two hours several times a day, often during video calls and client meetings. At the same time, doses that had previously worked cleanly began producing peak-dose dyskinesia: involuntary, writhing movements of the trunk and limbs that were visible to colleagues and made it difficult to type or use a mouse. Additional levodopa doses and adjunct medications (a dopamine agonist, rasagiline, and later entacapone) were added, but this shortened the interval between doses further without resolving either the off-periods or the dyskinesia.

Emotional and Psychological Impact

At 41, in a demanding technical leadership role, the patient found the unpredictability harder to manage than the symptoms themselves; he could not reliably plan which hours of the day would be usable for focused work or client-facing calls. He described scheduling meetings defensively around anticipated off-periods and increasingly working from home to avoid being seen mid-dyskinesia. The initial consultation focused on explaining that this pattern, a shrinking therapeutic window between off-periods and dyskinesia, is an expected consequence of long-term levodopa use in young-onset disease, and that it is precisely the scenario in which Deep Brain Stimulation offers the most benefit.

Why This Approach Was Chosen

The levodopa challenge test showed a greater than 70% improvement in motor score, a strong predictor of good response to Deep Brain Stimulation. His disease duration, young age, preserved cognition, and the specific combination of disabling off-periods alongside troublesome peak-dose dyskinesia are the classic profile for bilateral subthalamic nucleus Deep Brain Stimulation, which was chosen over the globus pallidus target specifically because it typically allows a larger reduction in levodopa dose, directly addressing the dyskinesia driving his functional impairment at work.

“In young-onset Parkinson’s disease, patients often reach this exact crossroads in their late thirties or early forties: still working full demanding careers, but caught between periods of being under-medicated and over-medicated within the same day. A strong levodopa response on challenge testing tells us the problem is fluctuation, not disease progression, and that is exactly what bilateral STN stimulation is designed to smooth out.” — Dr. Guruprasad Hosurkar.

Treatment Facts